Liquid Biopsy Matches Tissue for NSCLC Treatment Guidance
Patients with advanced non–small cell lung cancer and actionable mutations had similar progression-free survival whether treatment guidance came from tissue or circulating tumor (ct)DNA analysis using the Guardant360 assay, a matched retrospective comparison showed.
Source: OncLive